课题基金 / 基金详情

The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors

The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors
α2β1 整合素:对病原体的先天免疫
批准号:
8074980
负责人:
MARY M. ZUTTER
金额:
$32.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-01 至 2014-05-31

项目摘要

项目成果

MARY M. ZUTTER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们的目标是确定a2¿1整合素在肿瘤进展和转移的免疫调节中的作用,特别关注c-met和a2¿1整合素之间的相互作用。我们提供了令人兴奋的数据,a2¿1整合素不仅增强了对病原体的先天免疫反应,而且促进了病毒诱导的鳞状癌的进展和转移。在之前的资助期间,我们确定了C1q和collection家族蛋白作为a2¿1整合素的新配体,并证明了a2¿1整合素和c-met之间的串扰是肥大细胞激活和IL-6分泌所必需的。我们假设a2¿1整合素介导的免疫细胞和肿瘤细胞之间的相互作用调节肿瘤的进展和转移。在人乳头瘤病毒16型(HPV16)早期区基因在基底角化细胞中表达的上皮癌变转基因小鼠模型中,炎症、肥大细胞、T细胞和免疫复合物是肿瘤进展所必需的。在该模型中,50%的野生型小鼠发生浸润性鳞状细胞癌。我们生成了K14-HPV16/WT和HPV16/a2-null小鼠。在HPV16/a2- 1缺失小鼠中,a2¿1整合素缺失小鼠的肿瘤潜伏期和肿瘤生长没有改变,但与野生型小鼠相比,a2¿1缺失小鼠的肿瘤负荷和淋巴结转移的动物数量明显减少,这表明a2¿1整合素促进炎症和肿瘤进展。我们假设a2¿1整合素通过与c-met的相互作用和刺激免疫系统促进上皮癌的发生。我们结合小鼠模型、人类肿瘤样本和体外细胞生物学和分子技术提出了四个目标:具体目标1:确定a2¿1整合素表达促进肿瘤进展的机制。FOCUS - a2¿1整合素与K14-HPV16上皮癌变。特异性目的2:明确a2¿1整合素和HGF/c-met在肿瘤进展和转移中的串扰。FOCUS - a2¿1整合素与HGF/c-met相声。特定目的3:定义a2¿1整合素依赖的新血管生成和淋巴管生成调控。焦点-血液和淋巴内皮细胞。明确hpv阳性(+)和hpv阴性(-)头颈部鳞状细胞癌(HNSCC)中炎症、肥大细胞浸润、a2¿1整合素和c-met表达以及血管生成表型的功能和预后相关性。焦点-头颈部鳞状细胞癌。公共卫生相关性:肿瘤的进展和转移受宿主微环境(包括免疫系统细胞)的调节。这项提议的目标是研究细胞粘附受体,a2¿1整合素调节癌症的进展和转移。
英文摘要
DESCRIPTION (provided by applicant): Our goal is to define the role of a2¿1 integrin in the immune regulation of tumor progression and metastasis, with specific interest on the interplay between c-met and the a2¿1 integrin. We present exciting data that the a2¿1 integrin not only augments the innate immune response to pathogens, but promotes progression and metastasis of virus-induced squamous carcinoma. During the previous funding period we identified C1q and the collectin family of proteins as novel ligands for the a2¿1 integrin and demonstrated cross-talk between the a2¿1 integrin and c-met that was required for mast cell activation and the secretion of IL-6. We hypothesize that a2¿1 integrin-mediated interactions between immune cells and tumor cells regulate tumor progression and metastasis. Inflammation, mast cells, T cells and immune complexes are required for tumor progression in the transgenic mouse model of epithelial carcinogenesis in which the human papillomavirus type 16 (HPV16) early region genes are expressed in basal keratinocytes. In this model, invasive squamous cell carcinoma occurs in 50% of wild type mice. We generated K14-HPV16/WT and HPV16/a2-null mice. In HPV16/a2-null mice, tumor latency and tumor growth are not altered in mice lacking the a2¿1 integrin, but tumor burden and the number of animals with lymph node metastasis is markedly decreased in a2-null mice compared to wild type mice, suggesting that the a2¿1 integrin promotes inflammation and tumor progression. We hypothesize that a2¿1 integrin via interactions with c-met and stimulation of the immune system promotes epithelial carcinogenesis. We propose four aims using a combination of mouse models, human tumor samples, and in vitro cell biological and molecular techniques: SPECIFIC AIM 1: Determine the mechanism by which a2¿1 integrin expression promotes tumor progression. FOCUS - a2¿1 integrin and K14-HPV16 epithelial carcinogenesis. SPECIFIC AIM 2: Define cross-talk between the a2¿1 integrin and HGF/c-met in tumor progression and metastasis. FOCUS - a2¿1 integrin and HGF/c-met crosstalk. SPECIFIC AIM 3: Define the a2¿1 integrin-dependent regulation of neoangiogenesis and lymphangiogenesis. FOCUS - Blood and lymphatic endothelial cells. SPECIFIC AIM 4: Define the functional and prognostic relevance of inflammation, mast cell infiltration, a2¿1 integrin and c-met expression and the angiogenic phenotype in HPV-positive (+) and HPV-negative (-) squamous cell carcinoma of the head and neck (HNSCC). FOCUS - Squamous cell carcinoma of the head and neck. PUBLIC HEALTH RELEVANCE: Tumor progression and metastasis are regulated by the host microenvironment including cells of the immune system. The goal of this proposal is to study a cell adhesion receptor, the a2¿1 integrin that regulates cancer progression and metastasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Program Leaders
  • 批准号:
    8733554
  • 项目类别:
  • 资助金额:
    $7.49万
  • 财政年份:
    2013
  • 负责人:
    MARY M. ZUTTER
  • 依托单位:
Program Leaders
  • 批准号:
    8180520
  • 项目类别:
  • 资助金额:
    $19.99万
  • 财政年份:
    2010
  • 负责人:
    MARY M. ZUTTER
  • 依托单位:
Human Tissue Aquisition and Pathology Shared Resource
  • 批准号:
    8180573
  • 项目类别:
  • 资助金额:
    $24.32万
  • 财政年份:
    2010
  • 负责人:
    MARY M. ZUTTER
  • 依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
  • 批准号:
    8403773
  • 项目类别:
  • 资助金额:
    $29.04万
  • 财政年份:
    2009
  • 负责人:
    MARY M. ZUTTER
  • 依托单位:
海外基金